Cochlear synaptopathy, often called “hidden hearing loss,” is a condition of the inner ear affecting the connections between hair cells and the auditory nerve. Undetectable by standard audiograms, this disorder affects over a billion young people and up to 15% of adults, causing difficulty understanding speech in noise, tinnitus, and hyperacusis. Despite its prevalence, there is currently no specific treatment, leaving a significant unmet medical need.
Revolutionizing diagnostics with AI and machine learning
Cilcare, a French biotech company, aims to fill this gap by integrating artificial intelligence and machine learning into its research. These technologies enable the identification of previously inaccessible auditory biomarkers, facilitating more precise patient selection for clinical trials. They also refine the evaluation of treatment effectiveness, particularly for the company’s lead candidate, CIL001.
This process involves the large-scale analysis of auditory data collected during preclinical and clinical phases. The goal is to detect subtle indicators of cochlear synaptopathy and other auditory conditions. “Using AI in this domain ushers in a new era for diagnostics, with more robust data and significantly improved patient selection criteria,” explains Célia Belline, CEO of Cilcare.
Targeted treatments for a complex condition
Cilcare’s primary drug candidate, CIL001, is designed to repair damaged cochlear synapses that underlie the symptoms of cochlear synaptopathy. Delivered through a single injection, it aims to reconnect auditory fibers while enhancing auditory brainstem response (ABR) measurements. Phase 2a clinical trials are set to begin in Europe and the United States in 2025.
Additionally, Cilcare is advancing CIL003, currently in the preclinical phase, to broaden its portfolio and address other aspects of auditory disorders.
Solid funding to accelerate innovation
To advance these developments, Cilcare has closed a €40M Series A, including €21M raised in its latest funding round. The financing was supported by existing investors, such as SOFILARO, ARIS, SudPME, and UVM Health Capital, alongside new participants SHIONOGI & CO., LTD. and SPRIM GLOBAL INVESTMENTS PTE. LTD.
The funds will support two Phase 2a clinical trials, strengthen Cilcare’s R&D capabilities, and establish new strategic partnerships. By positioning itself as a leader in integrating AI into auditory sciences, Cilcare aims to transform the diagnosis and treatment of early-stage auditory disorders on a global scale.
